Stocks / BIIB
BIIB stock forecast
BIOGEN INC · Healthcare · Drug Manufacturers - General
Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.
BIIB is not among the 20 largest holdings published for 2026 Q4. See the portfolio
BIIB against the S&P 500
| Period | BIIB | S&P 500 (SPY) |
|---|---|---|
| 1 month | +7.7% | -4.7% |
| 3 months | +13.5% | -4.8% |
| Year to date | +42.9% | +7.9% |
| 1 year | +48.9% | +11.8% |
Total return, dividends included.
Key numbers
| Price | $251.41 |
| Market cap | 37.16 Billion |
| P/E (trailing 12 months) | 106.5 |
| P/S (trailing 12 months) | 3.6 |
| P/B (latest quarter) | 1.9 |
| Gross margin | 74.0% |
| Net profit margin | 3.4% |
| Return on equity | 1.9% |
| Beta | 0.4 |
As of October 28, 2026.
BIIB and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | 121.75 Billion | Greatly Outperform | BMY vs BIIB |
| PFE | PFIZER INC | 159.94 Billion | Greatly Outperform | PFE vs BIIB |
| GILD | GILEAD SCIENCES INC | 209.59 Billion | Outperform | GILD vs BIIB |
| AMGN | AMGEN INC | 240.11 Billion | Outperform | |
| MRK | MERCK & CO INC | 339.66 Billion | Greatly Outperform | |
| ABBV | ABBVIE INC | 505.56 Billion | Outperform |
Questions
What does the Upfront Investment model say about BIIB?
The model rates BIOGEN INC (BIIB) "Greatly Outperform" as of November 18, 2026, which means its medium-term return forecast is in the top fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the BIIB rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is BIIB in the Upfront Investment model portfolio?
BIIB is not among the 20 largest holdings published for 2026 Q4.
The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.